These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34936400)

  • 1. HIV Preexposure Prophylaxis Care Continuum Among Individuals Receiving Medication for Opioid Use Disorder, South Carolina, 2020-2021.
    Johnson J; Gormley MA; Bentley S; Baldwin C; Bublitz M; Heavner SF; Roth P; Litwin AH
    Am J Public Health; 2022 Jan; 112(1):34-37. PubMed ID: 34936400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
    McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
    Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated Bio-behavioral Approach to Improve Adherence to Pre-exposure Prophylaxis and Reduce HIV Risk in People Who Use Drugs: A Pilot Feasibility Study.
    Shrestha R; Altice FL; Karki P; Copenhaver MM
    AIDS Behav; 2018 Aug; 22(8):2640-2649. PubMed ID: 29582199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-delivery of HIV pre-exposure prophylaxis (PrEP) and HIV testing among publicly insured adolescents and young adults (AYA) receiving medication for opioid use disorder (MOUD).
    Herrera MC; Johnson J; Lim S; Morales KH; Wilson JD; Hadland SE; Metzger D; Wood S; Dowshen N
    Drug Alcohol Depend; 2024 Apr; 257():111132. PubMed ID: 38387256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder.
    Eger WH; Altice FL; Lee J; Vlahov D; Khati A; Osborne S; Wickersham JA; Bohonnon T; Powell L; Shrestha R
    Harm Reduct J; 2022 Oct; 19(1):120. PubMed ID: 36307817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing the HIV Pre-Exposure Prophylaxis Continuum: A Collaboration Between a Public Health Department and a Federally Qualified Health Center in the Southern United States.
    Clement ME; Johnston BE; Eagle C; Taylor D; Rosengren AL; Goldstein BA; Seña AC
    AIDS Patient Care STDS; 2019 Aug; 33(8):366-371. PubMed ID: 31233329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Interventions to Improve the HIV Continuum of Care and HIV Preexposure Prophylaxis in Kenya: A Model-Based Analysis.
    Luong Nguyen LB; Freedberg KA; Wanjala S; Maman D; Szumilin E; Mendiharat P; Yazdanpanah Y
    J Infect Dis; 2022 Mar; 225(6):1032-1039. PubMed ID: 33106850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attitudes and Intentions toward Use of HIV Pre-Exposure Prophylaxis (PrEP) among Adults Receiving Treatment for Opioid Use.
    Wyllie TJS; Brown JL; Meisman A; Bayyari N; Mangeot C; Sun Q; Mullins TLK
    Subst Use Misuse; 2024; 59(3):369-379. PubMed ID: 37917069
    [No Abstract]   [Full Text] [Related]  

  • 9. Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya.
    Mugwanya KK; Pintye J; Kinuthia J; Abuna F; Lagat H; Begnel ER; Dettinger JC; John-Stewart G; Baeten JM;
    PLoS Med; 2019 Sep; 16(9):e1002885. PubMed ID: 31479452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the Impact of PrEP Programs for Adolescent Sexual Minority Males Based on Empirical Estimates for the PrEP Continuum of Care.
    Hamilton DT; Rosenberg ES; Sullivan PS; Wang LY; Dunville RL; Barrios LC; Aslam M; Mustanski B; Goodreau SM
    J Adolesc Health; 2021 Mar; 68(3):488-496. PubMed ID: 32798099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-exposure prophylaxis (PrEP) indication and uptake among people receiving buprenorphine for the treatment of opioid use disorder.
    Beck L; Parlier-Ahmad AB; Martin CE
    J Subst Abuse Treat; 2022 Jan; 132():108506. PubMed ID: 34098202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the HIV pre-exposure prophylaxis care continuum.
    Nunn AS; Brinkley-Rubinstein L; Oldenburg CE; Mayer KH; Mimiaga M; Patel R; Chan PA
    AIDS; 2017 Mar; 31(5):731-734. PubMed ID: 28060019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of HIV Preexposure Prophylaxis Use Behaviors and HIV Incidence Among US Adults in an Integrated Health Care System.
    Hojilla JC; Hurley LB; Marcus JL; Silverberg MJ; Skarbinski J; Satre DD; Volk JE
    JAMA Netw Open; 2021 Aug; 4(8):e2122692. PubMed ID: 34436609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Willingness to initiate pre-exposure prophylaxis (PrEP) and its use among opioid-dependent individuals in drug treatment.
    Ni Z; Altice FL; Wickersham JA; Copenhaver MM; DiDomizio EE; Nelson LE; Shrestha R
    Drug Alcohol Depend; 2021 Feb; 219():108477. PubMed ID: 33422864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reaching Those Most at Risk for HIV Acquisition: Evaluating Racial/Ethnic Disparities in the Preexposure Prophylaxis Care Continuum in Baltimore City, Maryland.
    Schumacher CM; Tao X; Chandran A; Fields E; Price A; Greenbaum A; Jennings JM;
    J Acquir Immune Defic Syndr; 2021 Aug; 87(5):1145-1153. PubMed ID: 33883471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020.
    Tanner MR; Miele P; Carter W; Valentine SS; Dunville R; Kapogiannis BG; Smith DK
    MMWR Recomm Rep; 2020 Apr; 69(3):1-12. PubMed ID: 32324724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contingency Management and Pre-Exposure Prophylaxis Adherence Support Services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs.
    Sung ML; Viera A; Esserman D; Tong G; Davidson D; Aiudi S; Bailey GL; Buchanan AL; Buchelli M; Jenkins M; John B; Kolakowski J; Lame A; Murphy SM; Porter E; Simone L; Paris M; Rash CJ; Edelman EJ
    Contemp Clin Trials; 2023 Feb; 125():107037. PubMed ID: 36460267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
    Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE;
    BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Preexposure Prophylaxis Referrals From Public STI Clinics and Implications for the Preexposure Prophylaxis Continuum.
    Bhatia R; Modali L; Lowther M; Glick N; Bell M; Rowan S; Keglovitz K; Schneider J
    Sex Transm Dis; 2018 Jan; 45(1):50-55. PubMed ID: 28876282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential Impact of Interventions to Enhance Retention in Care During Real-World HIV Pre-Exposure Prophylaxis Implementation.
    Chan PA; Goedel WC; Nunn AS; Sowemimo-Coker G; Galárraga O; Prosperi M; Patel R; Mena L; Montgomery MC; Marshall BDL
    AIDS Patient Care STDS; 2019 Oct; 33(10):434-439. PubMed ID: 31584857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.